Advanced imaging of Alzheimer's Amyloid beta Oligomers in mouse and human post-mortem brain slices through conformational antibody fragments

Datasets include histological data obtained from experimental uses of antibody fragments generated through a proprietary “nanobody platform” and here exploited as innovative probes for imaging studies to recognize critical antigens on fixed brain tissues. In detail, small antibody fragments recognizing Alzheimer’s Aβ Oligomers (AβOs), namely “anti-AβO scFvs”, intrinsically equipped with unique features of conformation-sensitivity and sequence-specificity were tested in Alzheimer’s Disease (AD) relevant and control tissues. The anti-AβO scFvs, purified as recombinant proteins, were used for labeling procedures of post-mortem human brain slices from AD patients and mouse AD models, in comparison to amyloid-relevant full IgG antibodies. Preliminary results in confocal microscopy show that anti-AβO scFvs identify peculiar histological patterns of AβO deposition in comparison to conventional full IgG. Confocal microscopy experiments aimed at: i. optimizing protocols of immunolabeling with scFvA13 in brain slices from 5xFAD mouse model and ii. testing immunofluorescence procedures in slices from post-mortem brains of human AD patients. The following experimental groups were taken into consideration: i. Mouse brains: Tissues obtained from WT and 5xFAD mice (AD model) were used for a characterization of Amyloid pathology immunostaining with different full IgG antibodies (datasets 1-2) and for test and validation of scFvA13 anti-AβO “nanobody” immunolabeling in combination with amyloid-relevant full IgG antibodies (datasets 3-8). Human brains: Tissues obtained from Alzheimer post-mortem cases were used for a characterization of Amyloid pathology immunostaining with different full IgG antibodies (datasets 9-10) and for the immunolabeling with scFvA13 anti-AβO “nanobody” (validated in 5xFAD mice) in combination with amyloid-relevant full IgG antibodies (datasets 11-15).